Treatment Plan and Phases
Efforts to halt EMT, induce MET, and initiate apoptosis can be included in phase 2 of treatment. These may be grounded in aptamer-regulated exosomal therapy, where aptamers can serve as binding partners for relevant transcription factors and signaling pathway elements. Binding partners for these aptamers have yet to be determined, however, they should be specific for pancreatic cancer cells. Various treatments can be included inside the exosomes, such as miR200c or other miRNAs in the 200 family, or an apoptosis-inducing molecule such as ONC201. To maximize efficiency of treatment, phases 1 and 2 can overlap slightly so all pancreatic cancer cells throughout the body may be recognized effectively during phase 2. This is especially true for the ever-changing tumor microenvironment and the premetastatic niche, which both still need to be researched more.
Recent comments